Discrepancies between HMPAO and BCD SPECT imaging in brain tumors

Journal of Nuclear Medicine

Volumn 38, Issue 4, 1997, Pages 592-596

  Papazyan, J P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Brain perfusion; Brain tumor; Technetium 99m ECD; Technetium 99m HMPAO

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; BRAIN TUMOR; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROKE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CORONARY CIRCULATION; CYSTEINE; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; OXIMES; TECHNETIUM TC 99M EXAMETAZIME; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030978673     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Moretti JL, Caglar M, Weinmann P. Cerebral perfusion imaging tracers for SPEC!: which one to choose? J Nucl Med 1995;36:359-363.
2. Neirinckx RD, Canning LR. Piper IM, et al. Technetium-99m d,I-HMPAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 1987:28:191-202.
3. Andersen AR. Tccbnetmm-99m-D,L-hexamethylene-propyleneamine oximc (w'TcHMPAO): basic kinetic studies of a tracer of cerebral blood flow. Cerehrovase Hrain Melab Rev 1989:1:288-318.
4. Newton MR. Austin MC, Chan JG. McKay WJ, Rowe CC. Berkovic SF. Ictal SPECT using technctium-99m-HMPAO: methods for rapid preparation and optimal deployment of tracer during spontaneous seizures. J Nucl Med 1993:34:666 670.
5. Walovitch RC, Hill TC, Garrity ST, et al. Characterization of technetium-99m-L,EECD for brain perfusion imaging, part 1: pharmacology of technetium-99m-ECD in nonhuman primates. J Nucl Med 1989:30:1892-1901.
6. Walovitch RC, Franceschi M. Picard M, et al. Metabolism of 'WmTc-L,L-Hthyl cysteinate dimer in healthy volunteers. Neiiropharmucolog\- 1991:30:283-292.
7. Léveillé J, Demonceau G, Walovitch RC. Inlrasubject comparison between technetium-99m-ECD and technetium-99m-HMPAO in healthy human subjects. J Nucl .Vied I992;33.-480-484.
8. Tsuchida T, Nishizawa S. Yonekura Y, et al. SPECT images of technetium-99m-ethyl cysteinate dimer in cerebrovascular diseases: comparison with other cerebral perfusion tracers and PET. J Nucl Med 1994;35:27-31.
9. Nakagawara J, Nakamura J, Takeda R, et al. Assessment of postischemic reperfuiion and diamox activation test in stroke using WmTc-ECD SPECT. J Cereh Blood Flow Melab I994;14:S49-S57.
10. Slosman DO, Jacquier M, Pugin J, Rutenacht DA, Donath A. Polla BS. Nature of the cellular retention of HMPAO and ECD: an in vitro study [J. J Nucl ,vleii 1995;36:254P.
11. Jacquier-Sarlin MR, Polla BS, Slosman DO. Oxido-reductive state: the major dtterminant for cellular retention of 'Tc-HMPAO. J Nucl Med 1996;37:14I3- 1416.
12. Townsend DW, Wcnsveen M, Byars LG, et al. A rotating PET scanner using BGO block detectors: design, performance and applications. ./ Nucl Mud 1993;34:13671376.
13. Babich JW, Keeling F, Flower MA, et al. Initial experience with wmTc-HMPAO in the study of brain tumors. Etir J Nucl Med 1988; 14:39-44.
14. Rodrigues M, Fonseca AT. Salgado D, Vieira MR. WmTc-HMPAO brain SPEC in the evaluation of prognosis after surgical resection of astrocytoma. Comparison with other noninvasive imaging techniques (CT, MRI and 2(HTI SPECT). Nucl Med Commun 1993:14:1050-1060.
15. Lorberboym M, Segal D, Machac J, Sen C, Sacher M. Avid uptake of technetium99m-HMPAO by an intracranial plasmacytorna during carotid balloon test occlus on. J Nucl Med 1995:36:800-803.
16. Grünwald F, Menzel C, Pietsch T, Pavics L. Hufnagel A. Biersack H-J. Increased technetium-99m-HMPAO uptake Grade II astrocytoma. ./ Nucl Med 1995:36:804806.
17. Schwanz RB, Carvalho PA, Alexander E III, Eoeffler JS. Folkerth R, Holman UL. Radiation necrosis versus high-grade recurrent glioma: differentiation by using dual-isotope SPECT with 2'TI and wTc-HMPAO. Am J Neuroradiol 1991:12: 1187-1192.
18. Lindegaard MW. Skretting A, Hager B, Watne K. Lindegaard K-F. Cerebral and cerebellar uptake of WmTc-(d,I)-hexamethyl-propy!eneamine oxime (HMPAO) in patients with brain tumor studied by single-photon emission computerized tomography. Em-J Nucl Med I986;12:4I7-420.
19. Neirinckx RD, Burke JF, Harrison RC, Forster AM, Andersen AR. Lassen NA. The retention mechanism of technetium-99m-HMPAO: intracellular reaction with ghtathione. J Cereh Blood Flow Melab 1988;8:S4-S12.
20. Jacquier-Sarlin MR, Polla BS. Slosman DO. The cellular basis of ECD brain retenti 3n. J Nucl Med 1996:37:1694-1697.
21. Hall EJ. The oxygen effect and reoxygenation. In: Radiobiology for the radiologist. 4th ed. Philadelphia: J.B. Lippincott Co.; 1994.
22. Jansscn YMW, Van Houten B. Borm PJA, Mossman BT. Biology of disease: cell und tissue responses to oxydative damage. Lab Invest 1993:69:261-274.